FORM 4	
--------	--

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer
		(Check all applicable)
Huang Jane	BeiGene, Ltd. [ BGNE ]	
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	Director10% Owner
(Last) (First) (Windle)		X_ Officer (give title below) Other (specify below)
C/O MOURANT GOVERNANCE	12/14/2021	CMO, Hematology
SERVICES (CAYMAN), 94 SOLARIS		
AVENUE		
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)
CAMANA BAY, GRAND CAYMAN, E9 KY1-1108 (City) (State) (Zip)		X _ Form filed by One Reporting Person Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

						-	,			
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	Beneficial		
			Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Ordinary Shares								160055	D	
American Depositary Shares (1)	12/14/2021		М		1500	А	\$119.96	1500	D	
American Depositary Shares (1)	12/14/2021		s <u>(2)</u>		300	D	\$274.5367 ( <u>3</u> )	1200	D	
American Depositary Shares <sup>(1)</sup>	12/14/2021		<b>S</b> <sup>(2)</sup>		300	D	\$276.9533 <del>(4)</del>	900	D	
American Depositary Shares <sup>(1)</sup>	12/14/2021		<b>S</b> (2)		500	D	\$278.212 <u>(5)</u>	400	D	
American Depositary Shares (1)	12/14/2021		<b>S</b> (2)		100	D	\$278.79	300	D	
American Depositary Shares (1)	12/14/2021		<u>s(2)</u>		200	D	\$281.635 <u>(6)</u>	100	D	
American Depositary Shares (1)	12/14/2021		s <u>(2)</u>		100	D	\$284.52	0	D	

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative	rsion Date rcise f	 4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		1		Securities Underlying Derivative Security		Derivative Security (Instr. 5)	Securities Beneficially	Ownership Form of Derivative	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security		Code	V	(A)	(D)	Date Exercisable	Expiration Date		Amount or Number of Shares			Direct (D) or Indirect (I) (Instr. 4)	
Share Option (Right to Buy)	\$9.23 <u>(7)</u>	12/14/2021	М			19500	<u>(8)</u>	6/4/2029	Ordinary Shares	19500.0	\$0	211276	D	

### **Explanation of Responses:**

- (1) Each American Depositary Share represents 13 Ordinary Shares.
- (2) The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020.
- (3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$274.27 to \$274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$276.57 to \$277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$277.78 to \$278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
- (6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$281.49 to \$281.78,

inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

- (7) The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
- (8) These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.

Reporting Owners								
Departing Oxymer Neme / Address	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Huang Jane C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN, E9 KY1-1108			CMO, Hematology					

#### Signatures

/s/ Qing Nian, as Attorney-in-Fact 12/16/2021 \*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Note:

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.